Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 19/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16100412 | 0.96 | ENPP2 (0.40) | ENPP2KCNH2 | |
| SCHEMBL16099903 | 0.94 | FAAH (0.38) | ENPP2KCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16100542 | 0.93 | ENPP2 (0.41) | ENPP2KCNH2 | |
| SCHEMBL16102412 | 0.93 | ENPP2 (0.41) | ENPP2NPC1RAB9ASMN1; SMN2ATXN2 | |
| SCHEMBL16099997 | 0.92 | SMN1; SMN2 (0.39) | ENPP2NPC1RAB9ASMN1; SMN2ATXN2 | |
| SCHEMBL16100321 | 0.90 | FAAH (0.38) | ENPP2KCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16100243 | 0.90 | ENPP2 (0.38) | ENPP2KCNH2SMN1; SMN2 | |
| SCHEMBL16101871 | 0.90 | GRM5 (0.39) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16099815 | 0.90 | ENPP2 (0.41) | ENPP2NPC1RAB9ASMN1; SMN2ATXN2 | |
| SCHEMBL16101350 | 0.88 | SMN1; SMN2 (0.38) | ENPP2NPC1RAB9ASMN1; SMN2ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | ENPP2 1/4885KCNH2 2017/4885NPC1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.